IL135469A0 - Methods for treating psychosis associated with glucocorticoid related dysfunction - Google Patents

Methods for treating psychosis associated with glucocorticoid related dysfunction

Info

Publication number
IL135469A0
IL135469A0 IL13546998A IL13546998A IL135469A0 IL 135469 A0 IL135469 A0 IL 135469A0 IL 13546998 A IL13546998 A IL 13546998A IL 13546998 A IL13546998 A IL 13546998A IL 135469 A0 IL135469 A0 IL 135469A0
Authority
IL
Israel
Prior art keywords
methods
psychosis associated
treating psychosis
related dysfunction
glucocorticoid
Prior art date
Application number
IL13546998A
Other languages
English (en)
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of IL135469A0 publication Critical patent/IL135469A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13546998A 1997-10-06 1998-10-05 Methods for treating psychosis associated with glucocorticoid related dysfunction IL135469A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6097397P 1997-10-06 1997-10-06
PCT/US1998/020906 WO1999017779A1 (en) 1997-10-06 1998-10-05 Methods for treating psychosis associated with glucocorticoid related dysfunction

Publications (1)

Publication Number Publication Date
IL135469A0 true IL135469A0 (en) 2001-05-20

Family

ID=22032889

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13546998A IL135469A0 (en) 1997-10-06 1998-10-05 Methods for treating psychosis associated with glucocorticoid related dysfunction
IL135469A IL135469A (en) 1997-10-06 2000-04-04 Use of glucocorticoid receptor antagonists in the preparation of drugs for the treatment of psychosis associated with glucocorticoid-related disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL135469A IL135469A (en) 1997-10-06 2000-04-04 Use of glucocorticoid receptor antagonists in the preparation of drugs for the treatment of psychosis associated with glucocorticoid-related disorders

Country Status (17)

Country Link
US (2) US6150349A (xx)
EP (1) EP1023074B1 (xx)
JP (3) JP2001518509A (xx)
KR (2) KR100804558B1 (xx)
CN (3) CN1528315A (xx)
AT (1) ATE332696T1 (xx)
AU (1) AU747956B2 (xx)
CA (1) CA2302586C (xx)
CY (1) CY1106330T1 (xx)
DE (1) DE69835225T2 (xx)
DK (1) DK1023074T3 (xx)
ES (1) ES2268792T3 (xx)
IL (2) IL135469A0 (xx)
NO (1) NO327233B1 (xx)
NZ (1) NZ503250A (xx)
PT (1) PT1023074E (xx)
WO (1) WO1999017779A1 (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (en) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
US6620802B1 (en) 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
DE60124289T2 (de) * 2000-09-18 2007-09-06 Applied Research Systems Ars Holding N.V. Verfahren zur herstellung von 21-hydroxy-6,19-oxidoprogesteron (21oh-6op)
CA2440605C (en) * 2001-03-23 2012-01-10 Corcept Therapeutics, Inc. Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
NZ529456A (en) * 2001-05-04 2005-10-28 Corcept Therapeutics Inc Use of GR antagonists such as RU009 and RU044 to ameliorate the symptoms of delirium
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
NZ530724A (en) * 2001-07-23 2005-09-30 Corcept Therapeutics Inc Methods for preventing antipsychotic-induced weight gain
ES2314103T3 (es) * 2001-08-31 2009-03-16 Corcept Therapeutics, Inc. Metodo para inhibir deterioro cognitivo en adultos con sindrome de down.
HUP0500070A3 (en) * 2001-10-26 2012-09-28 Pop Test Cortisol Llc Use of (11betha,17betha)-11-(1,3-benzodioxol-5-yl)-17-(1-propynyl)-estra-4,9-dien-3-one for producing pharmaceutical compositions for the treatment of major depressive disorder
AU2002366217A1 (en) * 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
EP1534299A4 (en) * 2002-07-02 2007-04-11 Corcept Therapeutics Inc METHOD FOR TREATING PSYCHOSIS IN CONNECTION WITH INTERFERON-ALPHA THERAPY
WO2004054587A1 (en) * 2002-12-18 2004-07-01 University Of Zurich Treatment of neuro-psychiatric disorders
WO2004069202A2 (en) * 2003-02-04 2004-08-19 Corcept Therapeutics, Inc Antiglucocorticoids for the treatment of postpartum psychosis
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
WO2006060736A2 (en) * 2004-12-03 2006-06-08 The Children's Hospital Of Philadelphia A composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
CN100588393C (zh) * 2004-12-15 2010-02-10 上海三合生物技术有限公司 赛米司酮类用于治疗抑郁症的用途
US20060229505A1 (en) * 2005-04-08 2006-10-12 Mundt James C Method and system for facilitating respondent identification with experiential scaling anchors to improve self-evaluation of clinical treatment efficacy
CA2649894A1 (en) * 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
EP1987814A1 (en) * 2007-04-30 2008-11-05 Exelgyn Mifepristone pharmaceutical compositions and their methods of preparation
RU2327448C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Средство для лечения зависимости от этилового спирта и/или от наркотиков, фармацевтическая композиция, активный ингредиент фармацевтической композиции, способ лечения зависимости от этилового спирта и/или от наркотиков для лечения психосоматических и неврологических осложнений у алкоголиков и/или наркоманов
AU2008265898B2 (en) * 2007-06-15 2013-11-28 Research Triangle Institute Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
ES2762243T3 (es) * 2010-05-26 2020-05-22 Corcept Therapeutics Inc Tratamiento de distrofia muscular
JP5804395B2 (ja) * 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー 診断と治療のためのシステムおよび方法
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
EP3265127B1 (en) * 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
US10604807B2 (en) 2015-05-18 2020-03-31 Corcept Therapeutics, Inc. Methods for diagnosing and assessing treatment for Cushing's syndrome
WO2018074371A1 (ja) * 2016-10-21 2018-04-26 シチズン時計株式会社 検出装置
WO2021119432A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
US11878025B2 (en) * 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5348729A (en) * 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
WO1997037664A2 (en) * 1996-04-09 1997-10-16 British Technology Group Ltd. Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs

Also Published As

Publication number Publication date
JP5180125B2 (ja) 2013-04-10
CY1106330T1 (el) 2011-10-12
ES2268792T3 (es) 2007-03-16
KR100804558B1 (ko) 2008-02-20
KR20010024431A (ko) 2001-03-26
CN1187053C (zh) 2005-02-02
NO20001744L (no) 2000-04-05
CN1528315A (zh) 2004-09-15
EP1023074B1 (en) 2006-07-12
CA2302586C (en) 2008-06-10
DE69835225T2 (de) 2007-07-05
US6362173B1 (en) 2002-03-26
KR20070032822A (ko) 2007-03-22
AU747956B2 (en) 2002-05-30
US6150349A (en) 2000-11-21
WO1999017779A1 (en) 1999-04-15
NO327233B1 (no) 2009-05-18
NZ503250A (en) 2001-09-28
IL135469A (en) 2007-03-08
AU9683298A (en) 1999-04-27
JP2009051858A (ja) 2009-03-12
EP1023074A1 (en) 2000-08-02
JP2009132743A (ja) 2009-06-18
CA2302586A1 (en) 1999-04-15
DK1023074T3 (da) 2006-11-06
CN1919199A (zh) 2007-02-28
PT1023074E (pt) 2006-12-29
KR100840957B1 (ko) 2008-06-24
DE69835225D1 (de) 2006-08-24
ATE332696T1 (de) 2006-08-15
NO20001744D0 (no) 2000-04-05
CN1272788A (zh) 2000-11-08
JP2001518509A (ja) 2001-10-16

Similar Documents

Publication Publication Date Title
IL135469A0 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
AU9156901A (en) Chemokine receptor binding heterocyclic compounds
SG149693A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
CY1108562T1 (el) Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες
HUP0201184A2 (en) Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction
HK1035739A1 (en) Soluble t cell receptor
DK0946189T3 (da) Anvendelse af aktivatorer af CNTF (ciliær neurotrofisk faktor) receptor til behandling af adipositas
EP1109542A4 (en) NITROSED AND NITROSYLATED ANTAGONISTS OF THE ALPHA ADRENERGIC RECEPTOR, COMPOSITIONS AND USES THEREOF
LV12354A (lv) Centralo kanabinoidreceptoru antagonistu pielietojums estgribas regulesanai
NO20003534L (no) Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
AUPO755097A0 (en) Receptor agonist and antagonist
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
MY136097A (en) Methods for treating osteoarthritis using an estrogen agonist/antagonist
HUP0104780A3 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
MY127120A (en) A1 adenosine receptor antagonists
IL144031A0 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
WO2002006242A3 (en) 5-substituted 2-aryl-4-pyrimidinones
HU0105201D0 (en) The rapy for the treatment of andropause using estrogen agonists/antagonists and testosterone
DE69803883D1 (de) Neue verbindungen, welche antagonisten sind für p2-purinorezeptor 7-transmembran (tm) g-protein gekoppelte rezeptoren
EP1414445A4 (en) PARTIAL AGONIST ON THE MDNA RECEPTOR GLYCIN MODULATOR SITE FOR THE TREATMENT OF COGNITIVE DYSFUNCTION
HUP0302632A2 (hu) Antigesztagének alkalmazása gyorsított endometriális érés gátlására meddőségi kezelés alatt
NO20034916D0 (no) Anvendelse av glukokortikoid reseptor-spesifikke antagonister ved behandling av delirium
AU2001250528A1 (en) Agonists/antagonists of the gpr56 receptor as appetite control agents
DE60135773D1 (en) Assays
AU2002219192A1 (en) Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed